Study on Using Intensity Modulated Total Marrow Irradiation with Fludarabine/Busulfan for Transplant in High-Risk AML and Myelodysplastic Syndromes

Program Overview

This Phase II study is exploring whether adding intensity modulated total marrow irradiation (TMI) to the standard chemotherapy regimen of fludarabine and busulfan can better prepare patients with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for an allogeneic stem cell transplant. The goal is to improve the effectiveness of the transplant by using this combination treatment.

Description

In this study, patients will receive a combination of treatments to prepare for a stem cell transplant. This includes:

• Fludarabine, a chemotherapy drug, given through an IV for four days, starting five days before the transplant.
• Busulfan, another chemotherapy drug, given through an IV for four days, starting five days before the transplant.
• Thymoglobulin, an immune-suppressing drug, given through an IV for three days before the transplant, but only for patients receiving stem cells from unrelated or mismatched donors.
• Intensity modulated total marrow irradiation (TMI), a type of radiation therapy, given for three days before the transplant.

On the day of the transplant, patients will receive the stem cells. To prevent complications like graft versus host disease (GVHD), patients will also receive medications such as tacrolimus and methotrexate. After the transplant, patients will be monitored regularly to assess their recovery and the success of the treatment.

Eligibility Criteria

Locations